{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:56:16Z","timestamp":1781700976827,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.mehy.2018.06.013","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T20:42:00Z","timestamp":1529354520000},"page":"36-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Bone resorption and bone metastasis risk"],"prefix":"10.1016","volume":"118","author":[{"given":"Katlynn M.","family":"Mathis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Sturgeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate M.","family":"Winkels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Wiskemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jane","family":"De Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine H.","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2018.06.013_b0005","first-page":"1","article-title":"Cancer facts & figures 2016","volume":"2016","author":"American Cancer Society","year":"2016","journal-title":"Cancer Facts Fig"},{"key":"10.1016\/j.mehy.2018.06.013_b0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.critrevonc.2017.04.008","article-title":"Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases","volume":"115","author":"Body","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.mehy.2018.06.013_b0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.canep.2014.05.005","article-title":"Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients","volume":"38","author":"Harries","year":"2014","journal-title":"Cancer Epidemiol"},{"issue":"20","key":"10.1016\/j.mehy.2018.06.013_b0020","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.mehy.2018.06.013_b0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jbo.2013.09.001","article-title":"Incidence, consequences and treatment of bone metastases in breast cancer patients-experience from a single cancer centre","volume":"2","author":"Kuchuk","year":"2013","journal-title":"J Bone Oncol"},{"issue":"1","key":"10.1016\/j.mehy.2018.06.013_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2345-7","article-title":"Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer","volume":"16","author":"Diessner","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.mehy.2018.06.013_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3332\/ecancer.2017.715","article-title":"Bone metastasis risk factors in breast cancer","volume":"11","author":"Pulido","year":"2017","journal-title":"Ecancermedicalscience"},{"issue":"27","key":"10.1016\/j.mehy.2018.06.013_b0040","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2010.31.5069","article-title":"Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14","volume":"29","author":"Lipton","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.mehy.2018.06.013_b0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jpba.2004.10.007","article-title":"Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer","volume":"37","author":"Pectasides","year":"2005","journal-title":"J Pharm Biomed Anal"},{"issue":"12","key":"10.1016\/j.mehy.2018.06.013_b0050","first-page":"4423","article-title":"Impaired bone microenvironment: correlation between bone density and presence of disseminated tumor cells","volume":"31","author":"Kraemer","year":"2011","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.mehy.2018.06.013_b0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-007-9109-4","article-title":"The bone microenvironment in metastasis; what is special about bone?","volume":"27","author":"Bussard","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.mehy.2018.06.013_b0060","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev.pathmechdis.3.121806.151431","article-title":"The osteoclast: friend or foe?","volume":"3","author":"Novack","year":"2008","journal-title":"Annu Rev Pathol Dis"},{"key":"10.1016\/j.mehy.2018.06.013_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/421746","article-title":"Biology of bone tissue: structure, function, and factors that influence bone cells","author":"Florencio-Silva","year":"2015","journal-title":"Biomed Res Int"},{"issue":"12","key":"10.1016\/j.mehy.2018.06.013_b0070","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","article-title":"Minireview: the OPG\/RANKL\/RANK system","volume":"142","author":"Khosla","year":"2001","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.mehy.2018.06.013_b0075","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.tem.2012.03.008","article-title":"Estrogen and the skeleton","volume":"23","author":"Khosla","year":"2012","journal-title":"Trends Endocr Metab"},{"issue":"2016","key":"10.1016\/j.mehy.2018.06.013_b0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.breast.2016.06.022","article-title":"High prevalence of vitamin D deficiency in women with breast cancer: the first Chilean study","volume":"29","author":"Acevedo","year":"2016","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.mehy.2018.06.013_b0085","first-page":"645","article-title":"Association between vitamin D deficiency and breast cancer","volume":"33","author":"Shaukat","year":"2017","journal-title":"Pakistan J Med Sci"},{"issue":"5","key":"10.1016\/j.mehy.2018.06.013_b0090","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S8756-3282(02)00866-9","article-title":"Relationship between serum 25-hydroxyvitamin D and bone resorption markers in vitamin D insufficiency","volume":"31","author":"Jesudason","year":"2002","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.mehy.2018.06.013_b0095","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.coph.2015.03.005","article-title":"Parathyroid hormone: anabolic and catabolic actions on the skeleton","volume":"22","author":"Silva","year":"2015","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"10.1016\/j.mehy.2018.06.013_b0100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00002018-200528050-00004","article-title":"Ovarian failure manifestations and management","volume":"28","author":"Molina","year":"2005","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.mehy.2018.06.013_b0105","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ctrv.2012.02.008","article-title":"Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?","volume":"38","author":"Hadji","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.mehy.2018.06.013_b0110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/0284186X.2013.792992","article-title":"The effect of ovarian dysfunction on bone mineral density in breast cancer patients 10 years after adjuvant chemotherapy","volume":"53","author":"Vehmanen","year":"2014","journal-title":"Acta Oncol (Madr)"},{"issue":"3","key":"10.1016\/j.mehy.2018.06.013_b0115","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11914-015-0266-z","article-title":"Chemotherapy- and irradiation-induced bone loss in adults with solid tumors","volume":"13","author":"Wissing","year":"2015","journal-title":"Curr Osteoporos Rep"},{"issue":"3","key":"10.1016\/j.mehy.2018.06.013_b0120","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10549-010-0899-7","article-title":"Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?","volume":"123","author":"Cameron","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.mehy.2018.06.013_b0125","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00774-015-0679-x","article-title":"Combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil causes trabecular bone loss, bone marrow cell depletion and marrow adiposity in female rats","volume":"34","author":"Fan","year":"2016","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.mehy.2018.06.013_b0130","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-017-4308-3","article-title":"Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model","author":"Fan","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.mehy.2018.06.013_b0135","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1002\/jcp.23034","article-title":"The role of osteocyte apoptosis in cancer chemotherapy-induced bone loss","volume":"227","author":"Shandala","year":"2012","journal-title":"J Cell Physiol"},{"issue":"6","key":"10.1016\/j.mehy.2018.06.013_b0140","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.bone.2012.03.027","article-title":"Attenuated Wnt\/\u03b2-catenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats","volume":"50","author":"Georgiou","year":"2012","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.mehy.2018.06.013_b0150","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1359\/jbmr.060106","article-title":"Bone marrow cell differentiation induced by mechanically damaged osteocytes in 3D gel-embedded culture","volume":"21","author":"Kurata","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.mehy.2018.06.013_b0155","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1359\/jbmr.080207","article-title":"Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localized bone destruction","volume":"23","author":"Kogianni","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"12","key":"10.1016\/j.mehy.2018.06.013_b0160","doi-asserted-by":"crossref","first-page":"6088","DOI":"10.1210\/jc.2003-030712","article-title":"Effects of chemotherapeutic agents on the function of primary human osteoblast-like cells derived from children","volume":"88","author":"Davies","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.mehy.2018.06.013_b0165","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/ejh.12109","article-title":"Bone marrow osteoblast vulnerability to chemotherapy","volume":"90","author":"Genchevia","year":"2013","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.mehy.2018.06.013_b0180","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S8756-3282(02)00953-5","article-title":"The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts","volume":"32","author":"Bord","year":"2003","journal-title":"Bone"},{"issue":"14","key":"10.1016\/j.mehy.2018.06.013_b0190","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J Clin Oncol"},{"issue":"3421","key":"10.1016\/j.mehy.2018.06.013_b0195","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"The distribution of secondary growths in cancer of the breast","volume":"133","author":"Paget","year":"1889","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.mehy.2018.06.013_b0200","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis: metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.mehy.2018.06.013_b0215","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jcp.21576","article-title":"Targeted overexpression of bsp in osteoclasts promotes bone metastasis of breast cancer cells","volume":"218","author":"Tu","year":"2009","journal-title":"J Cell Physiol"},{"issue":"7515","key":"10.1016\/j.mehy.2018.06.013_b0220","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature13375","article-title":"miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2","volume":"512","author":"Krzeszinskia","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.mehy.2018.06.013_b0225","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.mehy.2018.06.013_b0230","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bone.2014.06.023","article-title":"Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis","volume":"66","author":"Haider","year":"2014","journal-title":"Bone"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987718300975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987718300975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T22:15:57Z","timestamp":1534803357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987718300975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":40,"alternative-id":["S0306987718300975"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2018.06.013","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone resorption and bone metastasis risk","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2018.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}